Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

Earlier we have shown the expression of a constitutively active receptor tyrosine kinase Axl in CLL B-cells from previously untreated CLL patients, and that Axl inhibitor TP-0903 induces robust leukemic B-cell death. To explore whether Axl is an effective target in relapsed/refractory CLL patients,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Sinha, Sutapa, Boysen, Justin C., Chaffee, Kari G., Kabat, Brian F., Slager, Susan L., Parikh, Sameer A., Secreto, Charla R., Call, Tim, Shanafelt, Tait D., Leis, Jose F., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324680/
https://ncbi.nlm.nih.gov/pubmed/30647852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26444
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki